STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2000

Primary Completion Date

June 30, 2003

Conditions
Leukemia
Interventions
DRUG

imatinib mesylate

Trial Locations (1)

07936

Novartis Pharmaceuticals Corporation, East Hanover

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY